Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
MANNKIND CORP incurred credit facility of $250.0 million with Blackstone Alternative Credit Advisors LP (as Blackstone Representative) at one, three or six month term SOFR (at the Company’s election), subject to a 2% f maturing August 6, 2030.
- Instrument
- credit facility
- Principal
- $250.0 million
- Counterparty
- Blackstone Alternative Credit Advisors LP (as Blackstone Representative)
- Rate
- one, three or six month term SOFR (at the Company’s election), subject to a 2% f
- Maturity
- August 6, 2030
- Event
- incurrence
Exact text from the filing
On October 7, 2025, the Company borrowed $250.0 million in delayed draw term loans to fund the Acquisition Price and the scPharma Debt Extinguishment.
View on SEC.gov
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
MANNKIND CORP amended credit facility of additional $175.0 million incremental delayed draw term loan with Blackstone Alternative Credit Advisors LP (as Blackstone Representative) at one, three or six month term SOFR (at the Company’s election), subject to a 2% f maturing August 6, 2030.
- Instrument
- credit facility
- Principal
- additional $175.0 million incremental delayed draw term loan
- Counterparty
- Blackstone Alternative Credit Advisors LP (as Blackstone Representative)
- Rate
- one, three or six month term SOFR (at the Company’s election), subject to a 2% f
- Maturity
- August 6, 2030
- Event
- amendment
Exact text from the filing
Pursuant to the Credit Agreement Amendment, among other things, the Lenders agreed to provide an additional $175.0 million incremental delayed draw term loan solely to finance a portion of the fees, premiums, expenses and other transaction costs incurred in connection with the transactions contemplated by the Merger Agreement
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
MANNKIND CORP completed an acquisition involving scPharmaceuticals Inc. for approximately $296.5 million (closed 2025-10-07).
- Action
- acquisition
- Counterparty
- scPharmaceuticals Inc.
- Consideration
- approximately $296.5 million
- Closing
- 2025-10-07
Exact text from the filing
Share outstanding immediately prior to the Effective Time. The aggregate cash paid by the Company and Purchaser in the Offer and the Merger at the Closing Date was approximately $296.5 million (the “ Acquisition Price ”), which was funded by the Company from its available cash on hand and net proceeds from borrowings under its Credit Agreement (as defined below). As
View on SEC.gov